← All trials
NCT02861534
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 20, 2016
- Primary completion
- Jan 10, 2020
- Completion date
- Jan 24, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 4872
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- MerckLead sponsor
- Inova Health SystemOverall official - principal investigator
- MerckStudy director
- University of AlbertaStudy chair
- BayerCollaborator
- Canadian VIGOUR CentreCollaborator
- Duke UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.